<DOC>
	<DOCNO>NCT02170909</DOCNO>
	<brief_summary>Study investigate compare safety , pharmacokinetics pharmacodynamics BIBR 1048 MS follow oral administration single ( 150 mg , 220 mg 300 mg ) multiple ( 150 mg 220 mg q.d . 150 mg b.i.d . ) rise dos healthy male subject Japanese Caucasian origin .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics BIBR 1048 MS Capsule Healthy Male Subjects Japanese Caucasian Origin</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Healthy male subject Japanese Caucasian origin accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate , respiratory rate tympanic body temperature ) , 12 lead ECG ( electrocardiogram ) , clinical laboratory test 1.1 No find deviate normal clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥ 20 Age ≤ 45 year 3 . Body mass index ( BMI ) ≥ 18 ≤ 25 kg/m2 4 . Japanese subject welldefined Japanese population , parent Japanese origin subject Japanese passport live ≤ 8 year outside Japan . 5 . Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation . 1 . Current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . An unwillingness male subject abstain sexual intercourse pregnant lactate woman , unwillingness male subject use adequate form contraception well female partner ( ) use another form contraception ( woman possibly become pregnant ) time single dose Day 1 Day 2226 ( endof study examination ) 3 . Current diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder 4 . History clinically significant orthostatic hypotension , clinically significant current past fainting spell blackouts 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator bleed disorder include prolonged habitual bleeding hematologic disease cerebral bleeding ( e.g . car accident ) concussion ( head trauma result injure brain ) without loss consciousness 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives , whichever short , respective drug prior administration trial 8 . Use acetylsalicylic acid ( ASA ) contain overthecounter medication , clopidogrel ticlopidine dipyridamole , chronic administration nonsteroidal antiinflammatory drug ( NSAIDs ) ( cyclooxygenase2 ( COX2 ) inhibitor exclude ) , coumadin like anticoagulant , chronic use corticosteroid , heparin fibrinolytic agent within 14 day prior administration trial . 9 . Participation another trial investigational drug within three month prior administration trial 10 . Smoker ( &gt; 10 cigarettes/day &gt; 3 cigars/day &gt; 3 pipes/day ) 11 . Inability refrain smoke trial day 12 . Alcohol abuse ( 21unit/week ; one unit approximately half pint beer , small glass wine one measure spirit ) 13 . History drug abuse 14 . Blood donation ( 100 mL within three month prior screen administration blood donation screen endofstudy examination ) 15 . Excessive physical activity ( within one week prior administration trial endofstudy examination ) 16 . Any laboratory value outside reference range clinical relevance 17 . Inability comply dietary regimen study centre 18 . Known hypersensitivity drug excipients 19 . History familial bleeding disorder 20 . Thrombocytes &lt; 150000/μL</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>